乳腺癌组织中miR-210表达与分子分型的相关性分析

发布时间：2018-02-14 17:53

  本文关键词： 浸润性乳腺癌 miR- 分子亚型　出处：《临床医药文献电子杂志》2017年26期 　论文类型：期刊论文

【摘要】：目的观察乳腺癌组织中miRNA-210的表达水平,分析其与乳腺癌临床病理中肿瘤分子亚型的关系。方法收集本院确诊的50例浸润性乳腺癌患者经手术切除的乳腺癌组织标本及正常乳腺组织(距癌肿边缘5cm),采用实时定量RT-RCR(q RT-PCR)法检测miRNA-210表达水平,收集对应乳腺癌患者的临床病理资料,分析乳腺癌组织中miRNA-210与肿瘤分子分型的关系。结果浸润性乳腺癌组织中miRNA-210在HER-2高表达型乳腺癌组织中表达最高,其次是三阴型乳腺癌,在Luminal B型的两个分型中表达相似,在Luminal A型中表达最低,差异有统计学意义(P0.05)。浸润性乳腺癌组中miRNA-210表达与患者年龄、肿瘤大小、组织分级及病理分期等方面的差异无统计学意义(P0.05),因此与其他临床病理参数无关。结论 miRNA-210在乳腺癌组织不同分子分型中表达水平不同,且与乳腺癌分子分型相关,可以作为乳腺癌分子分型诊断的参考及三阴型乳腺癌治疗的新突破。
[Abstract]:Objective to observe the expression of miRNA-210 in breast cancer. To analyze the relationship between tumor molecular subtype and breast cancer clinicopathology methods 50 breast cancer specimens and normal breast tissues (5 cm from the margin of cancer) were collected from 50 patients with invasive breast cancer confirmed in our hospital. The expression of miRNA-210 was detected by real-time quantitative RT-RCR(q RT-PCR. The clinicopathological data of breast cancer patients were collected to analyze the relationship between miRNA-210 and tumor molecular typing in breast cancer tissues. Results the expression of miRNA-210 in invasive breast cancer tissues was the highest in high expression of HER-2 breast cancer, followed by triple negative type breast cancer. The expression of miRNA-210 was similar in the two types of Luminal B, and the lowest in type A of Luminal, and the difference was statistically significant (P 0.05). The expression of miRNA-210 was correlated with the age and tumor size of the patients with invasive breast cancer. There was no significant difference in histological grade and pathological stage, so it was not related to other clinicopathological parameters. Conclusion the expression level of miRNA-210 in different molecular classification of breast cancer is different, and it is related to the molecular classification of breast cancer. It can be used as a reference for molecular typing diagnosis of breast cancer and a new breakthrough in the treatment of triple negative breast cancer.
【作者单位】： 山东青岛大学医学院附属医院乳腺外科;山东青岛大学医学院生物化学与分子生物学教研室;
【分类号】：R737.9
，

本文编号：1511269